Abstract 1833
Background
Although the personalized medicine has always focused on the genomic or proteomic characterization of tumor, medical imaging is still one of the major factors to guide therapy and to monitor the progression of the tumor. Radiomics is an emerging field that converts the medical image data into the mineable quantitative features via the automatically algorithms, and can server as a bridge between medical image, genomics and clinical-parameters. Serval studies have demonstrated that the radiomic-based model can predict outcome of RCC, but the correlation between radiomic features and histological subtypes of RCC is still unknown. The aim of this letter is to focus on the ability of radiomics to identify the histological subtypes and metastasis of RCC.
Methods
This study included Forty-four patients diagnosed with renal tumor. For each renal lesion, The CT images of volume of interest (VOI) were obtained semi-automatically by two experienced nuclear medicine physician, 85 texture features were extracted from each VOI using the first-order statistics features, Shape Based Features, Gray Level Neighboring Gray Level Dependence Matrix and Neighboring Gray Tone Difference Matrix.
Results
To investigate the value of radiomic features to capture phenotypic differences of RCC, we performed Unsupervised Clustering of patients with similar radiomic expression patterns. We analyzed the two main clusters of patients with clinical parameters, and found that the tumor clusters were statistically and significantly associated with primary tumor stage (P < 0.001), M-stage (P = 0.049) and benign (P = 0.037), wherein high T-stages, M-stage and tumor group showed in cluster II. RCC histology and N-stage (lymph-node) did not reach statistical significance for their association with the radiomic expression patterns (P = 0.165, 0.361, respectively). In addition, we analyzed the overall survival (OS) of the each radiomic features, and showed that P25, IMC1 and IMC2 were associated with OS (P = 0.002, 0.002, 0.016, respectively, log-rank test).
Conclusions
The radiomic features from medical images could be helpful in deciphering T-stages, metastasis and benign of RCC and may have potential as imaging biomarker for prediction of RCC overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
National Natural Science Foundation of China (No 81402117, 81671775), Natural Science Foundation of Zhejiang Province (No LY17H160043) and Qianjiang talent plan of Zhejiang Province (No QJD1602025).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract